Swedish Ibrance Registries Insights (SIRI)

See also
Status	Clinical Trial	Phase
Completed	`NCT02378337` - Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality	N/A
Completed	`NCT01953003` - Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer	Phase 3
Not yet recruiting	`NCT01395706` - ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes	Phase 2
Enrolling by invitation	`NCT05486520` - Low-field MRI for Breast Cancer Screening	N/A
Completed	`NCT05159778` - Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)	Phase 2
Active, not recruiting	`NCT03379428` - Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT02891681` - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment	N/A
Withdrawn	`NCT03261323` - Breast Reconstruction Following Breast Cancer in Very High Risk Patients	N/A
Recruiting	`NCT04669873` - Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery	N/A
Completed	`NCT02408393` - MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery	Phase 3
Completed	`NCT03289819` - Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC	Phase 2
Completed	`NCT02495363` - Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
Not yet recruiting	`NCT06251544` - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer	Phase 1
Completed	`NCT03159195` - Ibrance Real World Insights
Completed	`NCT03425656` - Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer	Phase 3
Recruiting	`NCT05033756` - Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO	Phase 2
Not yet recruiting	`NCT01641003` - Isolation and Characterization of Cancer Stem Cells Using iFP Technique	N/A
Active, not recruiting	`NCT05364450` - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors	N/A
Active, not recruiting	`NCT03435952` - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT	Phase 1
Active, not recruiting	`NCT02204098` - Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy	Phase 1

NCT number	NCT04654208
Study type	Observational
Source	Pfizer
Contact	Pfizer CT.gov Call Center
Phone	1-800-718-1021
Email	ClinicalTrials.gov_Inquiries@pfizer.com
Status	Recruiting
Phase
Start date	December 15, 2020
Completion date	December 31, 2022

Swedish Ibrance Registries Insights (SIRI) — SIRI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms